Feed aggregator

Novartis Tops Busy Week with Solid Tumor Combo Drug Approval

Biospace news - Thu, 06/23/2022 - 02:00
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.

New Variants Escape Antibody Responses of Vaccinated, Long COVID Affects 1 in 5

Biospace news - Thu, 06/23/2022 - 02:00
Although COVID-19 appears to be on the run in the U.S., there is still a threat of resurgence. Here’s a look at some of the most recent COVID-19 stories and research.

Study: Female Scientists Not Getting the Credit They Deserve

Biospace news - Thu, 06/23/2022 - 02:00
Female scientists are now quantitatively not getting the credit they deserve, according to a new study published in the scientific journal Nature.

Moderna, GSK, Sanofi, AstraZeneca and BioNTech Expand Global Ops

Biospace news - Thu, 06/23/2022 - 02:00
It's been a busy month for big biopharma companies looking to expand operations with Moderna, AstraZeneca, Sanofi and more are setting up new facilities internationally.

U.S. House Approves New Federal Biomedical Agency to 'Make the Impossible Possible'

Biospace news - Thu, 06/23/2022 - 02:00
In an overwhelming vote of support, the U.S. House of Representatives approved the creation of a new department within the National Institutes of Health that is focused on biomedical innovation.

Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology

Biospace news - Thu, 06/23/2022 - 02:00
DEM BioPharma has $70 million to get started on novel immunotherapeutics to treat cancer following a successful financing round.

Regeneron Breaks Ground on $1.8B NY Expansion Project

Biospace news - Thu, 06/23/2022 - 02:00
Regeneron has broken ground on a $1.8 billion expansion of its Tarrytown, NY facilities that will add at least 1,000 new full-time jobs.

NYC Life Sciences Sector Poised for High-Growth Phase

Biospace news - Thu, 06/23/2022 - 02:00
According to a recent report, the New York City Metro area is home to 7% of the U.S. population but contains 10% of all U.S. biochemists and biophysicists and 12% of U.S. chemists.

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Biospace news - Thu, 06/23/2022 - 02:00
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.

An Expert's Take on a Career in Neuroscience

Biospace news - Thu, 06/23/2022 - 02:00
BioSpace interviewed Dr. Heike Blockus, an associate research scientist at Columbia University. Blockus shared her thoughts on the neuroscience career path.

PhaseBio’s Reversal Agent for Astra’s Brilinta could Spell Success for Both

Biospace news - Thu, 06/23/2022 - 02:00
PhaseBio is working toward mitigating the surgical risks for cardiac patients taking antiplatelet therapies with bentracimab, which is currently in Phase III development.

Contraceptives Drugs Market Size Will Observe Substantial Growth by 2030 Wilmington, Delaware, United States: Childbearing at an early age has become an issue of concern and to prevent the deaths caused due to this aspect, contraceptives are essential. Gl

Biospace news - Thu, 06/23/2022 - 02:00
Precision BioSciences and Novartis are teaming up to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.

Biomarkers found that could be drug targets against a deadly form of brain cancer

World Pharma News - Wed, 06/22/2022 - 10:00
Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal.

Currently, the drug most often used to treat glioblastoma, temozolomide, is uniquely able to cross the blood/brain barrier to attack the tumor but resistance develops rapidly, and many patients do not survive for more than a year after diagnosis.

AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic

Biospace news - Wed, 06/22/2022 - 02:00
AbbVie filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for Qulipta for the preventative treatment of migraine.

Diversity Makes Clinical Trial Recruitment Easier and Outcomes Better

Biospace news - Wed, 06/22/2022 - 02:00
Decentralized clinical trials may cost more upfront, but can have huge returns on the back end, according to speakers at Informa Connect’s Decentralized Clinical Trials meeting.

COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure

World Pharma News - Tue, 06/21/2022 - 10:00
Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory on this so-called "COVID-19 rebound."

Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically

World Pharma News - Mon, 06/20/2022 - 10:00
Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manuscripts, reinforcing the transformational benefit of Zolgensma® (onasemnogene abeparvovec) when used early.

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

Biospace news - Sat, 06/18/2022 - 02:00
An FDA advisory committee voted against Acadia Pharmaceutical’s supplemental New Drug Application of Nuplazid tablets for the treatment of Alzheimer’s-related psychosis.

Novel drug combo activates natural killer cell immunity to destroy cancer cells

World Pharma News - Fri, 06/17/2022 - 10:00
Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. A new study led by Penn State College of Medicine scientists finds that another type of immune cell - natural killer cells - can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors.

Report: Merck Looks into Possible Buyout of Seagen

Biospace news - Fri, 06/17/2022 - 02:00
Pharmaceutical giant Merck is exploring a possible purchase of biotech company Seagen, according to The Wall Street Journal.